Altogether 43聽AS and 44聽healthy controls were included in the study. Anti-MCV and anti-hsp65 were determined in sera by commercial and in-house ELISA, respectively. Serum autoantibody levels were correlated with ESR, CRP, HLA-B27 status, smoking habits, pain intensity, BASDAI, BASFI and BASMI indices.
Patients with AS had significantly higher serum anti-MCV levels (17.3 U/mL, range: 8.3-31.5 U/mL) in comparison to healthy subjects (8.9 U/mL, range: 5.4-13.3 U/mL) (p < 0.01). Sixteen of the 43聽AS patients (37%) and none of the 44聽healthy controls (0%) were anti-MCV positive using the cut-off value recommended by the manufacturer (> 20 U/mL). The mean anti-hsp65 concentration in AS sera was 124.8 AU/mL (range: 27.2-1000 AU/mL), while controls exerted significantly lower anti-hsp65 levels (mean: 51.8 AU/mL; range: 22.5-88.5 AU/mL) (p < 0.001). Correlation analysis revealed that both anti-MCV positivity (r = 0.613; p = 0.012) and absolute serum anti-MCV levels (r = 0.553; p = 0.021) correlated with anti-hsp65 levels. Anti-MCV positivity also correlated with ESR (r = 0.437; p = 0.03).
Anti-MCV and anti-hsp65 may be novel biomarkers in AS.